Private Equity
Andrea Alms Video: Money In Motion 93 - Antibody Drug Conjugate (ADC) Market
January 2024 - Private Equity
TRANSCRIPT Hello, my name is Andrea Alms and I am a technology investor and financial manager. And this is your money in motion. One of the themes coming out of JPMorgan 2020 for health care conference was antibody drug conjugate. What is it? Antibody drug conjugates ADC are monoclonal antibodies. Engineered monoclonal antibodies are connected and combined with cytotoxic agents. An ideal ADC has the following features a monoclonal antibody that targets a specific cancer adjuvant while not harming healthy cells.
Ten ADCs have been approved by the FDA for clinical use. These drugs target a variety of antigens and cellular pathways and deliver different cytotoxic payloads. ADCs are not new from a conceptual perspective, A renewed interest and investment in these important category of drugs is now paying off with several FDA approved products, according to press. It is the global antibody drug conjugate market size was 9.04 billion in 2022 and it is projected to grow to 25.46 billion by 2032 at a corporate average growth rate of 10.91%.
At market markets, the market size was 9.7 billion in 2023 and expected to grow to 19.8 billion in 2028, growing at 15.2%. At Grandview Research, the market was 7.82 billion in 2022 and grow to 22.35 billion by 2030. And a cop out average growth rate of 11.2% averaging the averages. The market size is 8.1 billion at 12.4%. Compound average growth rate.
Thank you. This is your money, your money, in motion.